Legend: Palais des congrès de Montréal = CC, Le Westin Montréal = W, Intercontinental Montréal = I
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 547 | Wed, 8/7/2013, 10:30 AM - 12:20 PM | CC-220bc | |
| Contributed Oral Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations | |||
| Biopharmaceutical Section | |||
| Chair(s): Joyee Ghosh, The University of Iowa | |||
| 1: | Pairwise-False Discovery Rate Control Using Pairwise Weights — Bhramori Banerjee, Merck ; Sanat K. Sarkar, Temple University | ||
| 2: | The Distribution of the Difference of Two Proportions: An Application of Sample Size Calculations Using Bayesian Approach — Mohammad Sahtout ; Wijith Munasinghe, AbbVie | ||
| 3: | Latent Class Analysis for Asthma Patient Outcome Measures — Wen-Ling Kuo, Merck ; Davis Gates, Merck and Co. ; Ruji Yao, Merck | ||
| 4: | Practical Options for the Detection and Management of Sample Data Outliers — Alfred Barron, Janssen Research & Development | ||
| 5: | Statistical Methodology to Develop Robust Dengue qRT-PCR Assays — Lingyi Zheng, GCI, Sanofi Pasteur ; Linda Starr-Spires, GCI, Sanofi Pasteur | ||
| 6: | Point Estimation with Quantal Response Data: Parametric Bootstrap Estimator Beats the Corresponding MLE — Amy Schrader, University of Arkansas for Medical Sciences ; Ishwori Dhakal, University of Arkansas for Medical Sciences ; Reid D. D. Landes, University of Arkansas for Medical Sciences | ||
| 7: | Recent Developments in Scaled Average Bioequivalence — Pascal Guibord, Algorithme Pharma | ||
| 8: | Tipping Point Analyses: A Case Study — Teresa Norris, PPD ; Graham Carron, PPD | ||
| 9: | Area Under the Curve (AUC) Approach Using Last Observation Carried Forward (LOCF) vs. Mixed-Effects Model Repeated Measures (MMRM) in Analyzing Longitudinal Count Data — Rakhi Kilaru, PPD | ||
| 10: | Impact of Ignoring Correlations in Vision Clinical Trials — Ratna Revankar, Johnson & Johnson ; Gary Koch, The University of North Carolina-Chapel Hill ; Atsushi Kawaguchi, The University of North Carolina | ||
| 11: | In-House vs. Out-Source: Operational Models for Data-Monitoring Committees — Denka Markova, Axio Research Inc. ; William Coar, Axio Research ; Lynn Navale, Amgen | ||
| 12: | Calibration Problems with Panel Data Applied to Alzheimer's Disease Biomarkers — Huanli Wang, University of California, Davis ; Danielle Harvey, UC Davis ; Laurel Beckett, UC Davis | ||
| 13: | Effects of Randomization Methods on Hypotheses Tests in Some Clinical Trials — Shaocheng Liu, MTDA ; June Li, MTDA | ||
| 14: | Assessing the Cumulative Exposure Response in Alzheimer's Disease Studies — Jianing Di, Janssen R&D, LLC ; Xin Zhao, Janssen R&D, LLC ; Daniel Wang, Janssen R&D, LLC ; Ming Lu, Janssen R&D, LLC ; Michael Krams, Janssen R&D, LLC | ||
| 15: | Retrospective Assessment of Noninferiority in Rare Disease of Guillian-Barre Syndrome — Chunqin Deng, Grifols Inc. ; Junliang Chen, Grifols Inc. ; Kim Hanna, Grifols Inc. | ||
| 16: | Assessing the Actual Treatment Benefit with Non-Adherence to Study Drug in a Large Randomized Trial — Lulu R Sterling, Amgen Inc. ; Yumi Kubo, Amgen Inc. | ||
| 17: | Analysis of Two-Period Crossover Design with Binary Response Data — James Lee, Daiichi Sankyo Pharma Development ; John D.S. Hwang, B.R.S.I. ; Chyi-Hung Hsu, Janssen Research & Development | ||
| 18: | Meta-Analysis for All-Cause Death for Apixaban vs. Placebo or Control in SPAF Trials — Li Wang, Bristol Myers Squibb ; Weihua Tang, Bristol Myers Squibb | ||
| 19: | Meta-Analysis of Stem Cell Therapy on Stroke in Pre-Clinical Studies — Qing Wu, Mayo Clinic ; Bart Demaerschalk, Mayo Clinic ; Kay Wellik, Mayo Clinic ; Wenchun Qu, Mayo Clinic | ||
| 21: | A Proposed Modification to Hy's Law and Edish Criteria: Using Aggregated Historical Data of Oncology Clinical Trials/ Generally Healthy Patients' Data — Daniel Parks, GlaxoSmithKline ; Xiwu Lin, GSK ; Kwan Lee, GSK | ||
| 22: | Probability of Monoclonality — Aili Cheng, GlaxoSmithKline | ||
| 23: | Bayesian Analysis for Noninferiority Trial — Shu-Chih Su, Merck Research Laboratories ; G. Frank Liu, Merck Res Labs | ||
| 24: | Revisit Sample Size Estimation in Phase II Selection Designs — Zuoshun Zhang, Celgene Corporation ; Angela Hu, Celgene Corporation | ||
| 25: | Statistical Quantification of Drug-Related Arrhythmia — Kai-Fen Wang, GlaxoSmithKline ; Paul McAllister, GlaxoSmithKline ; Eric Rossman, GlaxoSmithKline | ||
| 26: | Evaluation of Drug Interaction in Combination Therapy: Which Statistical Methods Should Be Applied? — Qin Liu, The Wistar Institute ; Xiangfan Yin, The Wistar Institute | ||
| 27: | Simulation of Safety Data for Clinical Trials — Scott Diegel, University of Wisconsin ; John Kloke, University of Wisconsin ; Neil Baron, University of Wisconsin | ||
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.